A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma

NCT ID: NCT02792803

Last Updated: 2017-07-26

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE4
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-09-30
• Study Completion Date: 2017-09-30

Brief Summary

The purpose of the study is to provide evidence that the efficacy of Xalatan will be superior to Apo-latanoprost and Co-latanoprost in the reduction of intraocular pressure in patients with primary open angle glaucoma. The study will also aim to prove the tolerability of Xalatan in terms of ocular hyperemia will be equivalent to its generic counterparts.

Detailed Description

Since the introduction of Xalatan generic versions of latanoprost have entered the Canadian marketplace such as Apo-latanoprost (Apotex Inc.), Co-latanoprost (Cobalt Pharmaceuticals Co.) and Sandoz latanoprost (Sandoz Canada Inc.). The exact formulation of the different preparations of latanoprost may differ between manufacturers, although the active ingredient itself is not supposed to vary within a 15% tolerance. In a topical ocular medication in a multi-dose dispenser, the stability of the drug and its ability to penetrate the cornea into the eye may affect the efficacy of the drug.

There are no clinical trials to compare the efficacy of generic versions of latanoprost to Xalatan, nor are there any clinical trials comparing efficacy between the different generic versions. Empirical evidence based on clinical experience suggests that at least some of the generic versions of latanoprost may not be as effective as the branded version (Xalatan). Intraocular pressure is often observed to increase when switching from a branded to generic version of latanoprost, but the opposite is rarely if ever observed. The purpose of this study will be to compare the efficacy of Xalatan to two of the most popular generic versions of latanoprost available in Canada (Apo-latanoprost and Co-latanoprost).

Conditions

POAG; Primary Open Angle Glaucoma; Ocular Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Xalatan --> Apo-/Co-Latanoprost

Patients in this arm will be prescribed Xalatan for the first four week period of the study and one of the generics, Apo- or Co-Latanoprost, for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)

Group Type: EXPERIMENTAL

Xalatan

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Apo-Latanoprost

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Co-Latanoprost

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Apo-/Co-Latanoprost --> Xalatan

Patients in this arm will be prescribed one of the generics, Apo- or Co-Latanoprost, for the first four week period of the study and Xalatan for the second four week period. Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)

Group Type: EXPERIMENTAL

Xalatan

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Apo-Latanoprost

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Co-Latanoprost

Intervention Type: DRUG

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Interventions

Xalatan

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention Type: DRUG

Apo-Latanoprost

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention Type: DRUG

Co-Latanoprost

A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.

Intervention Type: DRUG

Other Intervention Names

02231493; Latanoprost; 02296527; 02254786

Eligibility Criteria

Inclusion Criteria

• Patients ≥ 18 years old, diagnosed with primary open angle glaucoma or ocular hypertension
• IOP currently controlled on prostaglandin analogue monotherapy (latanoprost, bimatoprost or travoprost), as judged by the investigator

Exclusion Criteria

• Best corrected visual acuity worse than 0.6 logMAR or 20/80 Snellen in either eye.
• Patients in whom the mean IOP in either eye at the screening exam visit is greater than 36 mmHg
• History of ocular trauma within the past six (6) months.
• History of ocular infection or ocular inflammation within the past three (3) months.
• History of chronic or recurrent severe inflammatory eye disease (i.e., scleritis, uveitis)
• History of severe or serious hypersensitivity to any components of the study medications.
• Any abnormality preventing reliable applanation tonometry of either eye.
• Intraocular surgery within the past six (6) months as determined by patient history and/or examination.
• Patients with cup/disc ratio greater than 0.80 in either eye.
• Patients with severe central visual field loss in either eye defined as a sensitivity less than or equal to 10 dB in at least two (2) of the four (4) visual field test points closest to the point of fixation. Visual field test must be within 6 months of eligibility assessment.
• History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment.
• Current use of ANY glucocorticoid administered by any route. Patient must have washed out of the glucocorticoid for at least 4 weeks prior to study entry.
• Use of any systemic prostaglandin or prostaglandin analogue within the last three months.
• Current use of topical non-steroidal antiinflammatory agents which inhibit cyclo-oxygenase and prostaglandin analogue synthesis.
• Any form of glaucoma other than open-angle glaucoma (with or without a pigment dispersion or pseudoexfoliation component).
• Current use of topical non-steroidal anti inflammatory agents which inhibit cyclo-oxygenase and prostaglandin analogue synthesis.
• Angle grade less than 2 (extreme narrow angle with complete or partial closure) as measured by gonioscopy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Allergan

INDUSTRY

Sponsor Role: collaborator

Dr. David Yan

OTHER

Sponsor Role: lead

Responsible Party

Dr. David Yan

M.D., F.R.C.S. (C)

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

David B Yan, M.D., F.R.C.S. (C)

Role: PRINCIPAL_INVESTIGATOR

Ophthalmic Diagnostic Services

Locations

Opthalmis Diagnostic Services

Toronto, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Jonathan Elin-Calcador

Role: CONTACT

jonathanec.ods@gmail.com

4165869626

Facility Contacts

Jonathan Elin-Calcador

Role: primary

jonathanec.ods@gmail.com

4165869626

Other Identifiers

Pro00012759

Identifier Type: -

Identifier Source: org_study_id